tradingkey.logo
tradingkey.logo
Suchen

HUTCHMED (China) Ltd

HCM
Zur Watchlist hinzufügen
10.780USD
+0.020+0.19%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
1.87BMarktkapitalisierung
19.94KGV TTM

mehr Informationen über HUTCHMED (China) Ltd Unternehmen

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

HUTCHMED (China) Ltd Informationen

BörsenkürzelHCM
Name des UnternehmensHUTCHMED (China) Ltd
IPO-datumMay 19, 2006
CEOCheng (Chig Fung)
Anzahl der mitarbeiter1811
WertpapierartDepository Receipt
GeschäftsjahresendeMay 19
Addresse48th Floor, Cheung Kong Center, 2 Queen's Road Central
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandHong Kong
Postleitzahl- -
Telefon85221281188
Websitehttps://www.hutch-med.com/
BörsenkürzelHCM
IPO-datumMay 19, 2006
CEOCheng (Chig Fung)

Führungskräfte von HUTCHMED (China) Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Mr. Charles George Rupert Nixon
Mr. Charles George Rupert Nixon
Group General Counsel
Group General Counsel
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von HUTCHMED (China) Ltd?

Die fünf größten Anteilseigner von HUTCHMED (China) Ltd sind: Dr. Renu Bhatia

Wie viele Institutionen halten Anteile an HUTCHMED (China) Ltd (HCM)?

Mit Stand vom 2026Q1 halten 139 Institutionen Anteile an HUTCHMED (China) Ltd, mit einem Gesamtmarktwert von etwa 5.33M, was 3.05% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -5943889.00 gestiegen.